Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ERAS vs SANA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ERAS Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 3–2 Matrix Metrics)

ERAS Overall Winner 6-Pillar Tally: ERAS 4 – 0 SANA (2 Tie) Matrix Metrics: ERAS 3 – 2 SANA

As of Nov 16, 2026, Erasca, Inc. (ERAS) is the stronger overall head-to-head candidate over Sana Biotechnology, Inc. (SANA) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ERAS carries a Unified Composite Score of 37.5/100 (SELL) at $15.11 (N/M Forward P/E, 0.0% operating margin), whereas SANA carries 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While SANA currently prints a higher short-term Unified Composite Score (44.3/100 HOLD vs. ERAS 37.5/100 SELL), ERAS captures the overall institutional head-to-head verdict (3–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: ERAS is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.4); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ERAS vs SANA
ERAS NASDAQ Head-to-Head Winner
Erasca, Inc. Common Stock
Pharmaceutical Preparations
$15.11
-3.51% 1D
Market Cap $5.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.30β · 80% Vol
Unified Composite Score
37.5 / 100 SELL
Tech 20.0 Fund 47.0 Flow 70.0 Mom 64.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -7.2%) with fading momentum, RSI 49
RSI-14: 49.4 · SMA20: $14.89 · SMA50: $14.93
SANA NASDAQ
Sana Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.88
-6.93% 1D
Market Cap $605.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.82β · 78% Vol
Unified Composite Score
44.3 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.0%), weak momentum, RSI 31
RSI-14: 30.6 · SMA20: $2.37 · SMA50: $2.68

6-Pillar Scorecard Institutional Category Breakdown (ERAS 4 – 0 SANA)

Columns: Metric · ERAS · SANA
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ERAS
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $5.5B $605.3M
3. Profitability & Quality ERAS
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -48.7% -79.5%
4. Balance Sheet & Cash Flow ERAS
Cash Generation (TTM) -$252M -$145M
Cash Flow Margin N/A N/A
Net Cash / Leverage $2.2M Net Debt (0.12x D/E) $13M Net Debt (0.30x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ERAS
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 84.2% (6th %ile) 105.5% (4th %ile)
Put/Call OI Skew N/A 0.61x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ERAS (3) vs SANA (2)
Institutional Metric ERAS SANA Criterion Row Edge
Market Capitalization
Scale
$5.5B $605.3M Larger Scale ERAS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-48.7% -79.5% Higher ROE ERAS
52-Week Range Position
Momentum
58% ($2–$24) 1% ($2–$5) Stronger Trend ERAS
Beta / 30D Volatility
Risk Regime
2.30β · 80% Vol 1.82β · 78% Vol Lower Realized Risk SANA
Unified Institutional Score
Composite Signal
37.5 / 100 (SELL) 44.3 / 100 (HOLD) Higher Composite SANA
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$252M ($2.2M Net Debt (0.12x D/E)) -$145M ($13M Net Debt (0.30x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ERAS +30.03 pp
ERAS: +12.85% · SANA: -17.18%
3M Horizon ERAS +31.69 pp
ERAS: -16.52% · SANA: -48.21%
6M Horizon ERAS +85.29 pp
ERAS: +47.13% · SANA: -38.16%
1Y Horizon ERAS +543.51 pp
ERAS: +494.88% · SANA: -48.63%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ERAS vs SANA. Trailing 12-month operating profitability (ERAS 0.0% vs SANA 0.0%) and valuation multiples (ERAS N/M vs SANA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ERAS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-48.7% · N/M
SANA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-79.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ERAS BREAKDOWN
87d in phase · OBV NEUTRAL
Current IV 84.2%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ERAS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SANA BREAKDOWN
57d in phase · OBV NEUTRAL
Current IV 105.5%
IV Percentile 4th %ile
Put/Call OI Skew 0.61x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SANA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ERAS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SANA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $605.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ERAS vs SANA Key Questions & Quantitative Answers

As of Nov 16, 2026, Erasca, Inc. (ERAS) is the stronger overall head-to-head candidate over Sana Biotechnology, Inc. (SANA) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ERAS carries a Unified Composite Score of 37.5/100 (SELL) at $15.11 (N/M Forward P/E, 0.0% operating margin), whereas SANA carries 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While SANA currently prints a higher short-term Unified Composite Score (44.3/100 HOLD vs. ERAS 37.5/100 SELL), ERAS captures the overall institutional head-to-head verdict (3–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: ERAS is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.4); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ERAS leads the Growth & Scale pillar: ERAS posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SANA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ERAS generates N/A in USD-normalized revenue versus N/A for SANA. In operating R&D and SG&A reinvestment, ERAS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SANA.

ERAS and SANA trade at balanced relative valuation multiples. ERAS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SANA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ERAS (-48.7% ROE) versus SANA (-79.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ERAS carries 84.2% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 80% Vol realized risk). By comparison, SANA carries 105.5% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.